GlaxoSmithKline plc (GSK) has confirmed that US District Judge Sue Lewis Robinson, the presiding judge in the US District Court for the District of Delaware, ruled in Pronova’s favour in Pronova’s patent litigation involving US Patent Nos. 5,656,667 (“’667 patent”) and 5,502,077 (“’077” patent) covering Lovaza. GSK already has marketing rights for Lovaza (omega-3-acid ethyl esters) in the US and Puerto Rico. The Court found Pronova’s patent claims are valid and would be infringed by Teva Pharmaceuticals USA, Inc. and Par Pharmaceutical Inc.
